Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 6 | Vintage Vibes

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

Benzinga

Asian shares mostly decline as worries continue over Trump's tariffs

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on investor sentiments

The Independent UK

These 3 Undervalued Stocks Could Surge as Value Rotation Nears

A rotation back into value stocks may be imminent in today's market, giving investors a chance to expose themselves into a catch up play.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

7 Shampoo Brands Facing Consumer Lawsuits

Hair care should make you look better, not worse. Yet several major shampoo brands are now facing serious legal challenges from consumers who claim these products caused hair loss, scalp irritation, and other injuries. These lawsuits highlight growing concerns about potentially harmful ingredients in everyday hair care products.

Grocery Coupon Guide

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the second quarter, before the opening bell on Wednesday, July 16.

Benzinga

Here's What to Expect From Johnson & Johnson's Next Earnings Report

Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a notable decline.

Barchart

Les Squires obituary

Other lives: Non-woven fabrics designer who created new materials for use in industry and agriculture

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

3 Top Dividend Stocks Analysts Are Bullish on Right Now

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

MarketBeat

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

Barchart

New documentary explores the Tylenol cyanide murders - and the reason tamper-proof seals are on everything

In 1982, seven people in Chicago died after taking Tylenol laced with lethal cyanide, causing fear and a change in consumer product safety. Two suspects emerged but there were no arrests or answers. Now, a new Netflix docuseries, out May 26, examines the decades-old mystery offering an exclusive interview with…

The Independent UK

‘A new form of mass murder’: the terrifying, twisty unsolved mystery of the Tylenol killer

One of the most shocking true crime stories of the 80s is re-investigated in Netflix docuseries Cold Case: The Tylenol Murders

The Guardian - US

3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider

MarketBeat

Kenvue Fights to Shield Brands Like Listerine and Tylenol Amid £112m Tariff Shock

Kenvue customers are expected to be prepared for price hikes as companies that sell directly to consumers grapple with rising costs.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Trump hints at tariff reprieve for pharma companies that bring operations back to US

He suggests drugmakers would get ‘a lot of time’ to repatriate manufacturing before facing levies

MarketBeat

3 Industry Behemoths Are Rewarding Investors With Dividend Bumps

See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.

The Guardian - UK

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

Fortune

Netflix stock has been nearly unscathed by Trump tariffs. Some think it could be Silicon Valley’s version of Johnson & Johnson

As recession fears mount on Wall Street, management is still reportedly setting ambitious long-term goals.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

The Independent UK

Johnson & Johnson expects $400 million in tariff-related costs, mostly related to China

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year

The Guardian - UK

‘Half the place would be blown to bits’: the Irish villages under threat from Trump’s tariffs

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

Euronews

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Kiplinger

Stock Market Today: Stocks Are Mixed Before Liberation Day

Markets are getting into the freewheeling rhythm of a second Trump administration.

Barchart

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

MarketBeat

Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.